Therapeutically armed bipartite conditionally-oncolytic Ads, such as Ad.PEG-E1A-mda-7 (Ad.PEG-CTV-m7 or Ad.CTV-m7) [9-12] in which replication is controlled by the progression elevated gene-3 promoter (PEG-Prom) resulting in simultaneous production of mda-7/IL-24, have wider applications for cancer therapy showing enhanced activity in killing cancer cells in vivo as compared to single conditionally-oncolytic Ads [9, 13, 14]. This evidence concerns the gene IL24 and cancer.